PML/RARα融合基因检测早幼粒细胞白血病微小残留病  

The detection of PML-RARα fusion gene in promyelocytic leukemia to monitor minimal residual disease

作　　者：黎承平[1] 李淑娈[1] 李维佳[1] 

机构地区：[1]昆明医学院第一附属医院血液科,昆明650032

出　　处：《临床血液学杂志》2009年第2期125-127,共3页Journal of Clinical Hematology

摘　　要：目的:PML/RARα融合基因在监测急性早幼粒细胞白血病(APL)微小残留病(MRD)中的意义。方法:诱导缓解及巩固维持治疗期间,采用筑巢式逆转录-聚合酶链反应(RT-PCR)技术检测患者骨髓细胞中PML-RARα融合基因的变化。结果:长期随访的18例完全缓解(CR)患者,2例分子学复发。其中1例发生于CR1后4个月,诱导缓解治疗后获CR2,CR2后2个月再次分子学与血液学的复发,诱导治疗1个疗程获得CR3;1例发生于CR1后74个月,诱导缓解治疗后获得CR2,随访结束时生存期已达106个月。结论:在CR期定期监测PML-RARα融合基因,可尽早发现分子学复发,及时治疗可避免血液学复发。Objective： To investigate the PML-RARα fusion gene on monitor minimal residual disease（MRD） in acute promyelocytic leukemia（APL）. Method：PML-RARα fusion gene was detected by RT-PCR in induction therapy,consolidation and maintenance therapy. Result： The long-term follow-up of 18 cases who achieved complete re- mission（CR）, two cases relapsed in molecular level. One case relapsed after 4 months of CR1 and achieved CR2 after induction therapy. However, molecular and hematological relapse occured again 2 months later after CR2 and it achieved CR3 after one induction therapy. The other case relapsed after 74 months and achieved CR2 by induction treatment, and survived for 106 months untile the end of follow-up. Conclusion：RT-PCR assay for detection of PML-RARα should be performed regularly during CR period to monitor molecular relapse. Hematological relapse could be potentially averted by modification treatment according to monitoring PML-RARα.

关 键 词：白血病 早幼粒细胞性 急性 PML-RARd融合基因 微小残留病 

分 类 号：R733.71[医药卫生—肿瘤]